BioMarin licenses new enzyme therapy for Fabry disease with $70M upfront payment

BioMarin Pharmaceutical has secured exclusive worldwide rights (excluding Korea) to develop and commercialize HM15421/GC1134A, a long-acting enzyme replacement therapy for Fabry disease currently in Phase 1/2 trials. The deal includes a $70 million upfront payment to GC Biopharma and Hanmi Pharm, with potential milestone payments up to $405 million plus royalties. This therapy could become the first subcutaneous enzyme replacement option for Fabry disease, addressing a rare genetic disorder with serious symptoms. BioMarin will handle further development and commercialization outside Korea, where GC and Hanmi retain rights.

BioMarin Pharmaceutical shares trade at USD 55.80 on Pluang as of Oct 29, 2026 20:02 WIB. The stock has a market cap of $10.84 billion and a 1-day change of -0.36%. Volume stands at 2,001,455 shares, reflecting steady investor interest in the health sector company.